Celgene International Sárl Release: Two Clinical Studies Evaluating Benefits of ABRAXANE® Combinations in Patients with Unresectable Melanoma Presented at American Society of Clinical Oncology

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (Nasdaq:CELG) today announced that results from two investigator initiated studies including ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), and bevacizumab in unresectable melanoma were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.